On Monday, September seventeen, 2018, the Antitrust Division of the United States Office of Justice (the “DOJ”) cleared Cigna’s proposed $67 billion acquisition of Specific Scripts, the country’s major pharmacy profit manager. While the transaction even now wants the acceptance of certain state regulatory companies, acquiring the DOJ’s acceptance was widely viewed as the transaction’s most considerable impediment to defeat.
Cigna – just one of the country’s major wellbeing insurers – announced its proposed acquisition of Specific Scripts again on March seven, 2018. Since then, Cigna and Specific Scripts have been capable to acquire regulatory clearances from sixteen of the 29 states essential for the transaction, and the acquisition was formally permitted by the shareholders on August 24, 2018. In Monday’s announcement, Cigna said that it expects the proposed transaction to shut by the stop of the calendar year.
While Cigna and Specific Scripts await the remaining state regulatory approvals for its transaction, a different considerable proposed transaction – CVS’s proposed $sixty nine billion acquisition of Aetna – continues to be less than DOJ evaluate. While it is unclear precisely when the DOJ will make its selection on the CVS-Aetna transaction, some view the DOJ’s acceptance of the Cigna-Specific Scripts transaction as a very good indication for the deal likely forward.
We will hold our readers posted in the coming months and months as additional developments become identified with each proposed transactions, such as our analysis of the potential effects on the health care place if they progress as anticipated.